CG Oncology, Inc. (CGON)
Develops an experimental virus therapy to treat bladder cancer patients who don't respond to standard treatments.
$71.74-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+172.7%
The outlook
CGON is trading near recent highs, sitting well above its 50- and 200-day moving averages. Analyst consensus leans Strong Buy with an average price target about 26% above the current price. The stock is positioned in the upper range of its 52-week trading band.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range90% of the way from its 52-week low to high
Price targetAvg target +26% vs current price
Analyst price target
~12-month · 13 analysts$90.69average target+26.4% vs now
Now $71.74
Low $80.00High $108.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$6.33B
52-wk high
$77.00
52-wk low
$23.65
50-day avg
$65.55
200-day avg
$56.22
Trailing P/E
—